About this podcast:
Recorded at the 2025 IO360º Summit, this podcast addresses how Project Optimus is reshaping dose selection from maximum tolerated dose to a balance of efficacy and safety. More specifically, this panel addresses FDA objectives for multi-dose selection, alternative dose-selection strategies with imaging, biomarkers and tumor burden analysis, the higher costs and longer timelines, and financial impacts for early-phase oncology companies.
Moderators
Wim Vos, PhD
CEO
Radiomics.bio
Greg Goldmacher, MD, PhD, MBA
Associate VP, Clinical Research; Head, Clinical Imaging & Pathology
Merck Research Laboratories
Ryan Sullivan, MD
Director, Center for Melanoma / Associate Professor
Massachusetts General Hospital / Harvard Medical School
Andrea Ferris,
President & CEO
LUNGevity
Speakers
Gideon Blumenthal, MD
VP, Clinical Development Oncology
Merck Research Labs
This content was created by The Conference Forum staff. The Fierce editorial team did not contribute to this work.